Acquired Hemophilia A Clinical Trials
2 recruiting trials for Acquired Hemophilia A. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Acquired Hemophilia A clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
The only sponsor on record for these trials is Takeda (2 trials).
The most frequently studied intervention is OBIZUR (drug, 1 trial), followed by Susoctocog Alfa (Genetical Recombination).
Track Acquired Hemophilia A trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea
Acquired hemophilia A (AHA) is a rare bleeding condition which prevents blood clotting. Acquired means that people are not born with this condition or have a family history of...
A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A
This study is a survey in Japan of Susoctocog Alfa (Genetical Recombination) intravenous injection used to treat participants with bleeding events of acquired Haemophilia A (AHA)....
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Acquired Hemophilia A, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Acquired Hemophilia A, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Acquired Hemophilia A, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.